Every guide on PsyAccess exists to help someone make a medical access decision. That obliges us to be precise about how our content is made: including where machines help and where humans decide.
How a guide is produced
1. Research from primary sources. Guides start with regulatory documents, national reimbursement rules, registry data and peer-reviewed publications. We do not source medical claims from news aggregators, clinic marketing or social media. Each guide links its sources inline, and catalog records name the registry they were verified against.
2. AI-assisted production, under editorial control. We use AI tools in research, drafting and structuring, and we state that here as policy: you should never have to guess. The controls are what matter: no text is published as generated, every claim is traced to a primary source, clinical content is reviewed by licensed clinicians, and a verified error in clinical content is corrected the same day. AI sets the pace of production; sources and reviewers determine what is published.
3. Human editing and fact-checking. An editor reviews every guide against its sources before publication: claims are traced back to the cited documents, figures are re-checked, and anything that cannot be traced is removed.
4. Clinical review. Pages that make clinical statements are reviewed by licensed clinicians: the medical reviewers below. Where a review has been completed, the page carries the reviewer's name, credentials and review date; a page never names a reviewer before the review has actually happened. A page-level "Medically reviewed" badge means the reviewer read the full material; a section-level note means the review covers that section.
5. Updates. Access rules change. Guides carry a last-updated date, catalog records carry a last-verified date, and registry-derived data is refreshed on a scheduled cadence.
What we never do
We do not accept payment for listings or rankings. We do not publish efficacy promises. We do not present screening tools as diagnosis. We do not write about treatments without naming their regulatory status, approved, off-label or investigational.
Medical reviewers
Our clinical pages are read by practising clinicians who have no stake in what this site recommends. This section names them, and says exactly what each of them signed off on.
Medical review covers our editorial content (guides). The catalogue is verified against official registers: records are not individually clinician-reviewed.
How the review works
Reviewers are independent. They are not employed by PsyAccess, they are not listed providers, and they have no commercial interest in anyone in our directory. They are asked to do one thing: check our clinical statements against evidence-based practice and current research, and flag anything that overstates a result, omits a material risk, or misdescribes a regulatory status.
Comments come back as a structured list: quoted fragment, correction, and whether the correction is critical or optional. We apply them, the reviewer confirms the corrected text, and only then does a name go on the page. Each reviewed page carries the review date; where the evidence moves, the page is re-reviewed rather than quietly edited.
Two levels of review are published, and we distinguish them deliberately:
Page level: “Medically reviewed by …” at the top of a guide means the reviewer read the whole guide.
Section level: a note next to a specific section means the review covers that section only. Our country access guides work this way: the shared clinical sections (what treatment involves, and risks) are reviewed, while the administrative and regulatory parts of the page are editorially fact-checked against primary sources rather than clinically reviewed.
Medical review does not make a page medical advice, and it is not an endorsement of any provider in the directory.
Reviewers
Dr. Amy Reichelt, PhD
Neuroscientist, chartered psychologist and psychotherapist
PhD·Canada
Dr. Reichelt is a neuroscientist, Chartered Psychologist (BPS) and registered psychotherapist with more than fifteen years spent turning brain science into clinically grounded mental-health care. She earned her PhD in behavioural neuroscience at Cardiff University and has published over seventy peer-reviewed scientific papers. She has also delivered a TEDx talk on the impact of junk food on the teenage brain.
She has completed advanced training in trauma therapy and psychedelic-assisted therapy, and her clinical and research interests sit exactly where this site’s questions do: how altered states and neuroplasticity are used therapeutically, what the evidence actually supports, and how screening and integration fit around a dosing session. In her Toronto practice, Cultivae, she works with anxiety, trauma and stress-related conditions using ACT, CBT and somatic, trauma-informed approaches.
Alongside clinical work she advises life-science and mental-health companies on clinical-trial strategy, translational neuroscience and psychedelic medicine development. She is also a medical reviewer for our sister publication, States of Mind.
Reviewed for PsyAccess
Psilocybin therapy: what the evidence shows
MDMA-assisted therapy: what the evidence shows
The clinical sections of every country access guide: what treatment involves, and risks
Arielle Tandowski is a public health professional working at the intersection of mental health, psychedelic science and medical cannabis. She holds a Master of Public Health (MPH) and is certified in Good Clinical Practice (GCP): the international ethical and scientific standard for research involving people, which is also the standard the clinical trials listed on this site run under.
Her background combines research, analytics and medical writing: she has worked as a research analyst and project coordinator in the medical cannabis industry, and has written everything from consumer health articles to scientific materials for clinicians and forensic psychiatric evaluations for legal audiences. Her academic work includes a peer-reviewed publication in the Journal of Studies on Alcohol and Drugs and an e-course on psychedelic-assisted therapy for mental health conditions.
For this site she reviews the screening side of the directory, the eligibility self-check and the brief validated self-checks, drawing on her training in research methods, literature review and health communication. She is also a medical reviewer for our sister publication, States of Mind.
Reviewed for PsyAccess
The eligibility self-check: screening logic and questions (/check/)
The PHQ-2 / GAD-2 mini self-checks and their source attribution
Physician, medical advisor, founder and CEO of 5SWAN
MD·Germany
Dr. Judanin is a German physician and healthcare entrepreneur working at the intersection of clinical medicine and digital care. As founder and CEO of 5SWAN, a physician-led telemedicine platform, he has spent years building structured, protocol-driven treatment pathways in medical cannabinoids, a field where, much as with ketamine, an established medicine is used in newer, closely supervised therapeutic settings.
His day-to-day work is the practical side of the questions this site covers: screening and contraindications, medication interactions, ongoing safety monitoring and outcome tracking for treatments delivered outside the traditional hospital visit. He takes part in Germany’s policy discussions on telemedicine and cannabis regulation, and regularly writes reviews and scientific assessments for clinicians and patients.
For this site he reviews the ketamine and esketamine evidence pages, checking our clinical statements (indications, contraindications, interactions and monitoring requirements) against the product information and the primary literature. He is also a medical reviewer for our sister publication, States of Mind.
Reviewed for PsyAccess
Ketamine for depression: what the evidence shows
Esketamine (Spravato): what the evidence shows
Ketamintherapie in Deutschland: the German-cluster overview, cost and side-effect guides
Esketamin-Nasenspray: Wirkung, Wirkeintritt und Wirkdauer, the German-cluster esketamine explainer
Ketamintherapie: Ablauf und was Sie erwartet, the German-cluster process guide
Esketamin-Nasenspray: Erfahrungen, the German-cluster patient-experience guide
Spravato oder Ketamin-Infusion? the German comparison (clinical sections)
Ketamin bei Depression: Studienlage und laufende Studien, the German-cluster evidence and trials guide
Clinical claims in the 14 German-language city guides: driving after a session, post-dose observation, GKV/Limitatio and chefärztliche Bewilligung coverage logic, self-pay price framing (section review, 2026-09-07)
Consultant anaesthetist and intensive care specialist
MD MRCS(Ed) EDAIC·Malta and the United Kingdom
Dr. Gauci is a consultant anaesthetist and intensive care specialist working at Mater Dei Hospital and Gozo General Hospital in Malta. He earned his medical degree at the University of Malta, is a Member of the Royal College of Surgeons of Edinburgh and holds the European Diploma in Anaesthesiology and Intensive Care (EDAIC), with earlier locum consultant work across several NHS trusts in the United Kingdom, including Poole, Yeovil, Cornwall and North Tees hospitals.
Anaesthesiology is the specialty that knows ketamine best: as an anaesthetic, in monitored sedation and in the physiology of blood pressure, airway and recovery that sits behind every supervised dosing session. That is the perspective he brings to this site: what monitored administration, contraindication screening and post-dose observation actually involve, checked against the product information rather than the marketing.
Beyond hospital practice he has spent years in expedition, transfer and resuscitation medicine: coordinating ICU-level aeromedical repatriations across Europe as chief medical officer of an air-ambulance service, and instructing for the European Resuscitation Council and Resuscitation Council UK. He is currently completing a Master’s degree in Extreme Medicine with the University of Exeter, and he is also a medical reviewer for our sister publication, States of Mind.
Reviewed for PsyAccess
Spravato (esketamine) vs ketamine infusions: the practical differences
Is ketamine a psychedelic? The classification, and why it matters
How to prepare for ketamine therapy: a practical checklist
Ketamine therapy in Scotland: NHS and private options (clinical sections)
We are adding reviewers, in particular psychiatrists practising in Europe. If you are a licensed clinician working in psychiatry, anaesthesia and critical care, addiction medicine or psychology, and you would consider reviewing this material, write to hello@psyaccess.health. We publish the reviewer's name, credentials and review date, and we ask for consent to do so before anything is published.
Corrections
If you find an error: clinical, factual or in a catalog record, write to hello@psyaccess.health or use the contact section. Corrections that affect medical meaning are fast-tracked: a verified clinical error is corrected the same day and re-reviewed, and the page's updated date reflects the change. Providers can request corrections to their listing via this form.